TSHA — Recent News Coverage
All news mentioning TSHA in ESEN's AI-graded feed
News stories with TSHA as an affected ticker. Each article is graded by ESEN AI for impact level and direction (up/down/flat) on TSHA. See /coverage/TSHA for the 30-day aggregate.
SEEKINGALPHA.COM
·
2026-08-12
LOW
NEUTRAL
CORR0.35
Taysha Gene Therapies, Inc. (TSHA) Q2 2026 Earnings Call Transcript
$TSHA
◈ ESEN AI
TSHA released its Q2 2026 earnings call transcript on August 11, 2026. This represents a scheduled disclosure of management commentary and financial results discussion rather than a catalyst-driven announcement. Earning…
MANILATIMES.NET
·
2026-08-11
LOW
NEUTRAL
CORR0.15
Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update
$TSHA
◈ ESEN AI
Taysha Gene Therapies (TSHA) completed enrollment in two pivotal trials for TSHA-102, a gene therapy candidate targeting Rett syndrome, a rare neurological disorder. The REVEAL trial enrolled 17 patients while the small…
MANILATIMES.NET
·
2026-08-07
LOW
NEUTRAL
CORR0.05
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
$TSHA
◈ ESEN AI
Taysha Gene Therapies (TSHA) disclosed a routine equity grant under Nasdaq Rule 5635(c)(4), an inducement mechanism permitting equity awards to new employees outside standard equity plans. The grant comprised 144,000 re…
FINANCE.YAHOO.COM
·
2026-07-15
LOW
NEUTRAL
CORR0.25
Taysha Gene Therapies (TSHA) is One of The Most Affordable Biotech Names to Invest In
$TSHA
◈ ESEN AI
Taysha Gene Therapies (TSHA) announced a public equity offering of 32.5 million shares at $6 per share, along with warrant components, representing a capital raise mechanism typical for early-stage biotech firms seeking…
MANILATIMES.NET
·
2026-06-25
NEUTRAL
NEUTRAL
CORR0.35
Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
$TSHA
◈ ESEN AI
Taysha Gene Therapies (TSHA) announced pricing for a substantial equity offering, issuing 32.5 million shares at $6.00 per share alongside pre-funded warrants at $5.999. This capital raise totals approximately $195 mill…
SEEKINGALPHA.COM
·
2026-06-24
NEUTRAL
BEARISH
CORR0.15
Taysha Gene Therapies launches $200M public offering; shares down (NASDAQ:TSHA)
$TSHA
◈ ESEN AI
TSHA initiated a $200M capital raise via equity and warrant offering, a typical financing mechanism for clinical-stage or revenue-constrained biotech firms requiring liquidity for operations, trials, or runway extension…
MANILATIMES.NET
·
2026-06-24
NEUTRAL
NEUTRAL
CORR0.15
Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
$TSHA
◈ ESEN AI
Taysha Gene Therapies (TSHA) announced a $200 million underwritten public offering of common stock and pre-funded warrants, a routine capital raise for clinical-stage biotech firms. The offering includes a standard 15% …
SEEKINGALPHA.COM
·
2026-06-23
NEUTRAL
NEUTRAL
CORR0.15
Taysha Gene Therapies, Inc. (TSHA) Discusses Longer-Term Clinical Data and Program Update for TSHA-102 in Rett Syndrome - Slideshow (NASDAQ:TSHA) 2026-06-23
$TSHA
◈ ESEN AI
Taysha Gene Therapies (TSHA) released updated clinical data and program information for TSHA-102, its candidate therapy targeting Rett syndrome, a rare neurological disorder. The company's disclosure through a slide dec…
SEEKINGALPHA.COM
·
2026-06-22
NEUTRAL
NEUTRAL
CORR0.15
Taysha Gene Therapies, Inc. (TSHA) Discusses Longer-Term Clinical Data and Program Update for TSHA-102 in Rett Syndrome Transcript
$TSHA
◈ ESEN AI
Taysha Gene Therapies (TSHA) released longer-term clinical data and a program update for TSHA-102, a gene therapy candidate targeting Rett syndrome, a severe neurological disorder. The disclosure represents a standard c…
EXPLORE OTHER FILTERS